NHI.no
Annonse
Informasjon

Leishmaniasis

Leishmaniasis er en sykdom som kan arte seg på ulike måter - fra relativt milde forløp til alvorlig livstruende sykdom. På verdensbasis tar denne sykdommen 20 000 til 30 000 liv hvert år.

Forekomst av sykdommen i verden er beregnet til å være omkring 1 million nye tilfeller per år. Foto: PHIL - CDC

Sist oppdatert:

9. feb. 2021

Dette dokumentet er basert på det profesjonelle dokumentet Leishmaniasis . Referanselisten for dette dokumentet vises nedenfor

  1. Markle WH, Makhoul K. Cutaneous Leishmaniasis: Recognition and treatment. Am Fam Physician 2004; 69: 455-60. PubMed
  2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-77. PubMed
  3. World Health Organization. Fact sheet: leishmaniasis. April 2017. http://www.who.int/ (last accessed 23 August 2017).
  4. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet 2018; 392: 951–70. PMID: 30126638 PubMed
  5. Reithinger R, Chappuis F. Leishmaniasis. Best Practice BMJ, last updated Nov 2017. bestpractice.bmj.com
  6. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671. PubMed
  7. Müller KE, Blomberg B, Tellevik MG, et al. Leishmaniasis i Norge. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.19.0171 DOI
  8. Hirve S, Kroeger A, Matlashewski G, et al. Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health. PLoS Negl Trop Dis 2017; 11: e0005889. PMID: 29023446 PubMed
  9. Blomberg B, Müller KE, Helgeland L, et al. En mann i 80-årene med leddgikt og vedvarende feber. Tidsskr Nor Legeforen 2019. doi:10.4045/tidsskr.18.0546 DOI
  10. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G and Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165: 969-77. PubMed
  11. Fletcher K, Issa R, Lockwood DN. Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, london. PLoS One 2015; 10: e0121418. PMID: 25831056 PubMed
  12. Folkehelseinstituttet. Leishmaniasis - veileder for helsepersonell. Sist oppdatert 26.01.2019. www.https
  13. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63: e202–64. PMID: 27941151 PubMed
  14. Blum J, Buffet P, Visser L, et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J Travel Med 2014; 21: 116–29. PMID: 24745041 PubMed
  15. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323: 419-22. PubMed
  16. Salah AB, Messaoud NB, Guedri E, et al . Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368: 524-32. New England Journal of Medicine
Annonse
Annonse